ReviewNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2017
Peroxisome proliferator activating receptor-γ and the podocyte.
Review in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- Mitochondrial dysfunction: the hidden catalyst in chronic kidney disease progression.Renal failure · 2025Review
- Pharmacological potential of Chinese botanical drugs in managing chronic kidney disease by targeting mitochondrial quality control.Frontiers in pharmacology · 2025Review
- Article
- PTHrP Promotes RBP4 Expression Under the Control of PPARγ in the Kidney.International journal of molecular sciences · 2024Article
- Nephroprotective effect of pioglitazone in a Wistar rat model of adenine‑induced chronic kidney disease.Experimental and therapeutic medicine · 2024Article
- Deficiency of Nuclear Receptor Coactivator 3 Aggravates Diabetic Kidney Disease by Impairing Podocyte Autophagy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2023Article
- PPARG agonist pioglitazone influences diurnal kidney medulla mRNA expression of core clock, inflammation-, and metabolism-related genes disrupted by reverse feeding in mice.Physiological reports · 2022Article
- Alternatively Spliced Landscape of PPARγ mRNA in Podocytes Is Distinct from Adipose Tissue.Cells · 2022Article
- Selective modulator of nuclear receptor PPARγ with reduced adipogenic potential ameliorates experimental nephrotic syndrome.iScience · 2022Article
- Peroxisome proliferator-activated receptor gamma and its natural agonists in the treatment of kidney diseases.Frontiers in pharmacology · 2022Review
- Peroxisome Proliferator-Activated Receptor Gene Knockout Promotes Podocyte Injury in Diabetic Mice.BioMed research international · 2022Article
- Mitochondria in Diabetic Kidney Disease.Cells · 2021Review
- The Role of Mitochondria in Acute Kidney Injury and Chronic Kidney Disease and Its Therapeutic Potential.International journal of molecular sciences · 2021Review
- The joint effect of PPARG upstream genetic variation in association with long-term persistent obesity: Tehran cardio-metabolic genetic study (TCGS).Eating and weight disorders : EWD · 2021Article
- Nuclear receptors in the kidney during health and disease.Molecular aspects of medicine · 2021Review
- Targeting Premature Renal Aging: from Molecular Mechanisms of Cellular Senescence to Senolytic Trials.Frontiers in pharmacology · 2021Review
- Shaping Up Mitochondria in Diabetic Nephropathy.Kidney360 · 2020Review
- Kynurenine Pathway in Chronic Kidney Disease: What's Old, What's New, and What's Next?International journal of tryptophan research : IJTR · 2020Review
- Arachidonic Acid Metabolism and Kidney Inflammation.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Over the past two decades it has become clear that the glomerular podocyte is a key cell in preventing albuminuria, kidney failure and cardiovascular morbidity. Understanding the key pathways that protect the podocyte in times of glomerular stress, which can also be therapeutically manipulated, are highly attractive. In the following review we assess the evidence that the peroxisome proliferator activating receptor (PPAR) agonists are beneficial for podocyte and kidney function with a focus on PPAR-γ. We explain our current understanding of the mechanisms of action of these agonists and the evidence they are beneficial in diabetic and non-diabetic kidney disease. We also outline why these drugs have not been widely used for kidney disease in the past but they may be in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.